implicity

News

Press releases

Press Release

Implicity secures $40M growth equity funding to scale its AI-driven cardiac monitoring platform globally

The round is led by growth fund IRIS alongside Five Arrows. Funding will fuel Implicity’s next phase of growth in the US through local commercial hires, build on its established leadership across Europe, and accelerate further AI investment. Implicity already serves over 250 medical centers and monitors 120,000+ patients daily across the US, France, and Germany.

Cambridge, MA, USA and Paris, France — September 9, 2026

Cambridge, MA, USA and Paris, France, September 9, 2026 – Implicity, a global leader in AI-driven cardiac remote monitoring, has secured a $40 million funding round led by European tech growth capital firm IRIS, alongside Five Arrows, the alternative assets arm of Rothschild & Co.

Enabling clinicians to act on cardiac data at scale

Remote patient monitoring has become the standard of care in cardiology following the 2023 HRS/EHRA/APHRS/LAHRS Expert Consensus1. Today, care teams manage more sources than ever, from cardiac implantable electronic devices to heart failure monitoring. While each new data stream provides valuable clinical insight, it also adds complexity for the clinicians piecing the full picture together. Too much time is spent navigating multiple systems and triaging alerts to identify events that require action. This administrative burden reduces time available for direct patient care, potentially delaying responses to the events that matter most.

Implicity helps to solve this with a single, AI-driven platform that aggregates, normalizes, and analyzes data across the full continuum, regardless of device manufacturer. It also integrates with EHRs to streamline providers’ workflow. By bringing every signal into one intelligent view, Implicity lets clinicians spend less time searching through the noise and more time on patient care.

“I didn’t become a physician to manage data — I became one to treat patients,” said Dr. Arnaud Rosier, electrophysiologist, CEO and co-founder of Implicity. “This funding lets us care for patients at scale, catching the information through the noise to provide the best possible care — and that’s the future of cardiology I’ve been chasing since my first year as an electrophysiologist.”

Dr. Arnaud Rosier, Electrophysiologist, CEO & Co-Founder of Implicity

Proven clinical impact and market traction

Unlike traditional remote monitoring solutions, Implicity has built deep clinical credibility through its FDA-cleared AI algorithms and extensive real-world evidence. Patients monitored with Implicity have seen 26% reduction in mortality and 4% reduction in hospitalizations2, compared to those on conventional remote monitoring. SignalHF†, Implicity’s heart failure prediction algorithm, gives clinicians early visibility into a patient’s heart failure risk to support earlier identification and intervention.3 The platform’s ECG Analyzer‡ feature also reduces false alarms by up to 76%4,5, so clinicians spend less time sorting through alerts and more time with the patients who need them most.

The fundraising will support Implicity’s next phase of growth in the US. The company has built its hospital network on the ground from its Cambridge, MA base, earning the endorsement of clinicians and forging partnerships with local physicians. The round will be used for commercial hiring to widen that footprint and the development of US-specific features for one of the world’s largest healthcare markets. It will also fund continued investment in the company’s AI and innovation roadmap — including the next generation of Heart Failure prediction algorithms — to better serve medical teams and optimize care for remotely monitored patients.

“In the evolving healthtech landscape, long-term success requires a rare combination of robust technology, strict regulatory clearance, and undeniable clinical utility. Implicity has proven to be a highly trusted partner to complex health systems because its platform directly addresses the administrative and operational crisis facing hospital workforces today. We are thrilled to back the team as they cement their leadership in the US market and drive the next phase of digital healthcare infrastructure.”

Nicolas Herschtel, Partner at IRIS’ Growth team

“Implicity is a rare company where clinical superiority, regulatory credibility and genuine patient impact come together at scale. By turning fragmented cardiac data into action, it improves outcomes for patients while relieving the operational pressure on hospital teams. This is precisely the kind of sustainable, mission-driven business we seek to support.”

François-Xavier Lehman, Director at Five Arrows

About Implicity

Implicity is a digital medtech company specializing in cardiac remote monitoring. Its platform embeds proprietary algorithms, certified as medical devices, that improve clinical efficiency and predictive accuracy. The company’s independent, universal platform monitors patients with cardiac implantable electronic devices (CIEDs) and heart failure, turning their data into actionable insights for cardiologists and medical teams. Implicity supports medical teams across Europe and the United States in delivering more efficient, predictive, and proactive cardiac care.

About IRIS

IRIS is a European Growth and Venture capital equity firm specialized in tech, investing in seed, Series A, late stage, and growth. With offices and teams in Berlin, Munich and Paris, and a keen understanding of their markets and a robust international network, IRIS is a selective partner to the upcoming scale-ups and tech giants, helping them increase their visibility, business reach, and impact across the world. IRIS investments include, among others, Adjust, Braincube, Escape, Exotec, Kyriba, Jedox, LeanIX, LumApps, Open-Xchange, pyck, Red Points, Shift Technology, Spinergie, SurePay, Talend, Talon.one and Zeta Global. For more information, visit www.iris.vc

About Five Arrows

Five Arrows is the alternative assets arm of Rothschild & Co and has more than €34 billion in assets under management, with offices in Paris, London, New York, Los Angeles, San Francisco, and Luxembourg. This investment was made through the Five Arrows Sustainable Investments (FASI) fund, a direct minorities SFDR Article 9 fund. For more information, please visit: https://www.rothschildandco.com/en/five-arrows/multi-strategies/fasi/

  1. †SignalHF is an FDA-cleared Class II medical device, see the instructions for use for more information.
  2. ‡IM007 ILR ECG Analyzer is an FDA-cleared Class II medical device, see the instructions for use for more information.
  3. 1Ferrick AM, Raj SR, Deneke T, et al. “2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic.” Heart Rhythm. 2023;20(9):e92-e144. doi:10.1016/j.hrthm.2023.03.1525.
  4. 2Varma N, Marijon E, Vicaut É, et al. Impact of a universal monitoring system (“third party”) on outcomes of ICD patients: A nationwide study. Heart Rhythm. 2025;22(10):2661-2668. doi:10.1016/j.hrthm.2024.11.029.
  5. 3Varma N, Boveda S, Ibnouhsein I, Faedda G, Rosier A, Singh J. Heart failure events prediction algorithm for patients implanted with multi-brand CIED. Europace. 2024;26(Suppl 1):euae102.553. doi:10.1093/europace/euae102.553.
  6. 4Varma N, Wadhwa M, Lazarus A, Faedda G, Mabo P, Crespin E. Performance of a cloud-based AI solution for reducing false positive alerts in implantable cardiac monitors detected episodes. Europace. 2026;28(Suppl 1):euag105.043. doi:10.1093/europace/euag105.043.
  7. 5Marijon E, Crespin E, Leclercq C, Faedda G, Mabo P, Barraud J, Varma N. PO-01-235: Performance of a new cloud-based AI solution reducing false positive alerts in implantable cardiac monitor episodes on top of manufacturer AI algorithms. Heart Rhythm. 2026;23(4 Suppl):S294-S295. doi:10.1016/j.hrthm.2026.03.1775.

IMPLICITY®, Inc., a Delaware corporation with offices located at 185 Alewife Brook Pkwy 210, Cambridge, MA 02138 USA, file number 5917973.

Press Release

Study shows Implicity’s new agnostic cloud-based AI algorithm further reduces false alerts even after manufacturer AI filtering in modern devices

New HRS data extends EHRA findings with a specific analysis of next-gen ILRs, demonstrating that, on top of manufacturer-embedded AI, Implicity filters out 61.6% of false positives while maintaining 98.3% sensitivity*.

Cambridge, MA, USA — April 25, 2026

CAMBRIDGE, Mass., April 25, 2026 (GLOBE NEWSWIRE) -- Implicity, a leader in remote patient monitoring and cardiac data management solutions, today announced the latest findings presented at the Heart Rhythm Society (HRS) 2026.

The new HRS data extends on research presented earlier this month at the European Heart Rhythm Association (EHRA) Congress, which showed why false-positive alerts persist even in modern implantable loop recorders (ILRs). The follow-on HRS study specifically focused on the latest AI-equipped ILRs, examining whether layering Implicity’s new, universal cloud-based AI algorithm on top of proprietary manufacturer algorithms could further reduce false alerts.

In a review of 483 cases from 324 patients using AI-equipped devices, Implicity’s next-generation ILR ECG Analyzer successfully reclassified 61.6% of false-positive alerts in interpretable episodes while maintaining 98.3% sensitivity, helping reduce the workload for clinicians without compromising patient safety.

“Manufacturer filtering has clearly advanced, whether it happens in the device, in the cloud, or through a combination of both. But even in these newer systems, residual false-positive alerts still remain and continue to burden clinical teams. The findings from our HRS study demonstrate that a manufacturer-agnostic analysis layer can substantially reduce that remaining noise while maintaining the high sensitivity needed to protect patient safety,”

Arnaud Rosier, MD, PhD, electrophysiologist, CEO, and co-founder of Implicity

Implicity’s next-generation ILR ECG Analyzer is designed to act as an agnostic second-layer for residual alerts that remain after the initial manufacturer filters. Operating in the cloud and compatible with all major brands, Implicity’s new universal algorithm applies the most sophisticated neural networks, drastically reducing false positives without compromising patient safety.

This 'dual AI' approach does more than just streamline remote cardiac monitoring workflows; it also reduces alert fatigue by providing clinical teams with highly accurate, trustworthy data. With greater confidence in the data, clinicians can spend less time on noise and more time focusing on meaningful cardiac events.

“Newer AI-enabled ILRs do provide a cleaner data stream with fewer obvious artifacts, but they are not perfect, and the false positives that remain are often more subtle and clinically ambiguous. Those are exactly the alerts that still require careful adjudication. In a remote monitoring workflow, that matters enormously, and any technology that can safely mitigate ILR-related false-positive alerts is significant.”

Niraj Varma, MD, PhD, Professor of Medicine and Consultant Electrophysiologist at the Cleveland Clinic

These findings follow evidence presented at EHRA examining why false-positive alerts persist across modern ICM devices. In that work, investigators identified guideline-based interpretation gaps and signal-detection issues as key drivers of non-actionable alerts and showed that even in AI-equipped devices, 32.9% of episodes remained non-actionable, with another 30.6% deemed indeterminate. Together, the EHRA and HRS analyses highlight both the mechanisms behind persistent false positives and the potential for a universal, cloud-based AI approach to help address them across all devices—including those with or without proprietary AI.

Implicity’s next-generation ILR ECG Analyzer Algorithm (V2) is not FDA cleared yet.

About Implicity

Implicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure. Implicity’s platform provides critical health information augmented by FDA-cleared AI** algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes while optimizing workflows. With access to the Health Data Hub—a gateway to one of the world’s largest databases of heart disease patients encompassing nearly the entire French cardiac patient population—Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 110,000 patients in over 250 medical facilities across the US and Europe. To learn more, visit www.implicity.com or schedule a meeting with the Implicity team. Contact Daniel Martin, Vice President for US Sales, at daniel.martin@implicity.com or visit Booth #1819 at HRS 2026.

Media Contact

Samantha Choinski
eMedia Junction
samantha@emediajunction.com

  1. *The version of ILR ECG Analyzer evaluated in this study (V2) is not yet FDA cleared. Results may not be directly applicable to the currently cleared version.
  2. **SignalHF is an FDA-cleared Class II medical device, see the instructions for use for more information. IM007 ILR ECG Analyzer is an FDA cleared Class II medical device and CE marked Class I (under MDD) medical device, see the instructions for use for more information.

Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes. IMPLICITY®, Inc. a Delaware corporation with offices located at 185 Alewife Brook Pkwy 210, Cambridge, MA 02138 USA, file number 5917973.

Press Release

EHRA 2026 Studies Reveal Why False Positives Persist in AI-Equipped Implantable Cardiac Monitors

April 14, 2026

Research identifies guideline-based interpretation gaps and signal-detection issues behind non-actionable alerts and shows how an additional cloud-based AI layer can significantly reduce clinician review burden while maintaining high sensitivity

Cambridge, Mass., April 14, 2026 – Implicity, a leader in remote patient monitoring and cardiac data management solutions, today revealed new research presented at the 2026 European Heart Rhythm Association Congress (EHRA) examining why false-positive alerts remain a persistent challenge in implantable cardiac monitors (ICMs)—even in devices equipped with manufacturer AI algorithms. While physicians experience this burden every day, the findings provide new insight into why it persists, identifying guideline-based interpretation gaps and signal-detection issues as key drivers of non-actionable alerts across modern ICM platforms.

In a cross-manufacturer analysis of 2,659 rhythm episodes from 1,710 patients implanted with ICMs from Medtronic, Biotronik, Abbott, and Boston Scientific, findings revealed that even in AI-equipped devices, 32.9% of episodes were still non-actionable, with another 30.6% deemed indeterminate. Among devices without proprietary AI algorithms, 45.4% of episodes were non-actionable and 20.1% indeterminate.

To conduct the analysis, an independent expert adjudication committee applied a standardized annotation framework aligned with international electrophysiology guidelines to determine whether device-detected episodes met the diagnostic criteria for clinically meaningful arrhythmias.

The findings provide new insight into why false-positive alerts persist even as device algorithms have evolved. Investigators found that many alerts stem from how device algorithms interpret rhythm signals relative to guideline-defined arrhythmia criteria. When those interpretations diverge from clinical definitions, benign rhythms or signal artifacts, such as premature ventricular contractions or electrical noise, may be labeled as clinically significant events.

The analysis also identified specific signal-detection mechanisms contributing to these alerts. Episodes labeled as cardiac “pause” events emerged as a major driver, with 46.8% ultimately determined to be false positives caused by R-wave undersensing, where the device fails to detect a heartbeat and incorrectly interprets the signal as a pause.

“False-positive alerts remain one of the biggest operational challenges in remote cardiac monitoring,” said Niraj Varma, MD, PhD, Professor of Medicine and Consultant Electrophysiologist at the Cleveland Clinic. “Every episode flagged by an implantable cardiac monitor must be reviewed by a clinician, yet even devices equipped with manufacturer AI algorithms still generate a substantial number of non-actionable alerts. When interpretation varies across device platforms and guideline definitions are not consistently applied, it becomes more difficult for physicians to quickly determine which events truly require clinical attention.”

Building on these findings, investigators conducted a second analysis, also presented at EHRA, to examine whether an additional AI layer could help address these persistent false-positive alerts. The study evaluated the Implicity™ ILR ECG Analyzer*, a cloud-based algorithm designed to analyze ICM transmissions across multiple manufacturer platforms using a standardized guideline-based framework.

The results showed that Implicity’s cloud-based AI algorithm maintained very high sensitivity for detecting clinically meaningful arrhythmias—98.3% in AI-equipped devices and 94.3% in non-AI models—while filtering a substantial proportion of non-actionable alerts. Specificity reached 61.6% and 75.6% respectively, with a consistent positive predictive value of approximately 74% across both groups, demonstrating reliable diagnostic performance across different generations of implantable cardiac monitors.

“Remote monitoring only works if clinicians can trust the alerts they receive,” said Arnaud Rosier, MD, PhD, electrophysiologist, CEO, and co-founder of Implicity. “When a large share of those alerts are non-actionable, the burden is not just operational—it diverts valuable clinical time from patients who may truly need attention. Our data shows that adding a standardized, guideline-based AI layer can reduce that noise while maintaining the high sensitivity needed to detect clinically meaningful arrhythmias.”

The research presented at EHRA is part of Implicity’s broader clinical program focused on improving the accuracy and efficiency of remote cardiac monitoring. Additional data will be presented at the Heart Rhythm Society (HRS) Scientific Sessions, April 23–26, 2026, in Chicago.

To schedule a meeting with the Implicity team, contact Daniel Martin, Vice President for US Sales, at daniel.martin@implicity.com or visit Booth #1819 at HRS 2026.

About Implicity

Implicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure.

Implicity’s platform provides critical health information augmented by FDA-cleared AI3 algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes while optimizing workflows. With access to the Health Data Hub, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 110,000 patients in over 250 medical facilities across the US and Europe. To learn more, visit www.implicity.com

Media Contact:

Samantha Choinski

eMedia Junction

samantha@emediajunction.com

Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes

  1. *The version of ILR ECG Analyzer evaluated in this study (V2) is not yet FDA cleared. Results may not be directly applicable to the currently cleared version

Press Release

Implicity’s EVIDENCE-RM Study Demonstrates Marked Improvement in ICD Patient Outcomes

Comprehensive analysis of real-world data shows significant clinical and medico-economic advantages of Implicity’s universal, alert-based remote monitoring platform.

April 24, 2025

Cambridge, Mass., April 24, 2025 – IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, today unveiled new findings from its EVIDENCE-RM study1. Leveraging extensive data from the French National Health Data System (SNDS), the study demonstrated clear clinical and medico-economic benefits associated with Implicity’s universal monitoring system (UMS) compared to conventional, manufacturer-specific systems, including Abbott, Biotronik, Boston Scientific, and Medtronic.

The study, recently published in Heart Rhythm, analyzed clinical outcomes and costs for over 69,000 patients with implantable cardioverter-defibrillators (ICDs) and defibrillators with cardiac resynchronization therapy (CRT-Ds). Patients remotely monitored using Implicity’s platform showed increased survival rates and a reduction in both the number and duration of all-cause and heart failure-related hospitalizations, resulting in substantial healthcare cost reductions. Key findings attributed to Implicity’s IM0092 platform include:

  • 26% reduction in mortality (HR, 0.74; 95% CI, 0.73–0.77; P=.001)
  • 4% decrease in HF hospitalizations, total corrected healthcare costs, and mean duration of hospitalization
  • 8% decrease in hospital-related costs, primarily driven by decreased costs in cardiovascular disease care
  • Incremental Cost-Effectiveness Ratio (ICER) of approximately -$112 USD (-103€) per Day Alive and Out of Hospital (DAOH) based on the French Healthcare System

“Managing patients with ICDs and CRTs presents considerable challenges, since they are at high risk of hospitalization due to arrhythmias and heart failure, » said Dr. Niraj Varma, Professor of Medicine and Director, Cardiac Pacing & Tachyarrhythmia Devices at the Cleveland Clinic. « The EVIDENCE-RM study clearly demonstrates that a universal monitoring solution operating alert-based remote monitoring can significantly reduce these risks, improving patient outcomes and substantially lowering healthcare costs. This is an important advancement in our ability to proactively manage patients with ICDs and CRTs.”

« These findings mark a pivotal moment in remote cardiac care and prove Implicity’s effectiveness with unparalleled clinical results, » stated Implicity CEO Dr. Arnaud Rosier. « A 26% reduction in mortality and better use of healthcare resources highlight the impact of universal remote monitoring, driven by AI, over fragmented manufacturer-specific systems. Implicity is committed to driving innovation so that every cardiac patient receives proactive, efficient care.”

About Implicity

Implicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure.

Implicity’s platform provides critical health information augmented by FDA-cleared AI3 algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 100,000 patients in over 200 medical facilities across the US and Europe.

Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes

  1. 1Varma et al., “Impact of a universal monitoring system (‘third party’) on outcomes of ICD patients: A nationwide study,” Heart Rhythm, 2024.
  2. 2IM009: 2021. Manufacturer: Implicity. IM009 is a software as a medical device (SaMD) intended to be used as an adjunct of a remote monitoring platform to follow-up target population patients. IM009 is compatible with devices with remote monitoring feature such as cardiac implantable electronic devices and connected weight scales. The three main intents of IM009 are to (1) label observations generated by medical devices according to predefined categories, (2) create clinically relevant observations for worsening atrial fibrillation and/or rapid weight gain in the context of heart failure, based on data recorded by the device and (3) label Atrial Fibrillation burden observations generated by cardiac implantable electronic device (CIED) as to be hidden or relevant for health care provider based on patient’s anticoagulation status. Hence, IM009 is designed to reduce the workload burden of healthcare providers/professionals in charge of reviewing the observations received from the patients’ devices. IM009 is not intended for use in life supporting or sustaining systems or Alarm devices and as a solely means of diagnosis. It is offered to healthcare providers/professionals on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. Class I, according to Medical Device Directive 93/42/EEC. See the instructions for use for more information. Covered under the conditions defined in Article L. 162-52 of the French Social Security Code.
  3. 3IM007: 2021. ILR ECG ANALYZER created by Implicity is intended to be used by qualified healthcare professionals for the assessment of arrhythmias in Insertable Cardiac Monitor (ICM) ECG data. ILR ECG ANALYZER supports downloading and analyzing data recorded in compatible formats from ICMs. This version of the ILR ECG ANALYZER only supports ECG data from Medtronic ICMs. ILR ECG ANALYZER is intended to be electronically interfaced with other computer systems (remote monitoring platforms) that supply the ECG data to ILR ECG ANALYZER and receive the output of ILR ECG ANALYZER (analysis) for viewing by healthcare professionals. ILR ECG ANALYZER provides ECG signal processing and analysis, to detect asystole, bradycardia, atrial tachycardia or atrial fibrillation, ventricular tachycardia, normal rhythm and artifacts. ILR ECG ANALYZER is not for use in life supporting or sustaining systems or ECG monitor and Alarm devices. ILR ECG ANALYZER interpretation results are not intended to be the sole means of diagnosis. It is offered to physicians and clinicians on an advisory basis only in conjunction with the physician’s knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information. ILR ECG ANALYZER is interfaced with the compatible remote monitoring platform from which it receives compatible ICM data file input (Medtronic LNQ11 Medtronic REVEAL XT 9529 Medtronic REVEAL DX 9528) and to which it transmits the output. Read carefully all instructions before use. Results: sensitivity: 98.64 % (509/516), false positive rate: 24.03 % (68/283). FDA cleared Class II medical device and CE marked Class I medical device (under medical device directive 93/42).
    SignalHF FDA cleared Class II medical device and CE marked Class IIa (under MDR) medical device. Manufacturer: Implicity. The SignalHF System is intended for use by qualified healthcare professionals (HCP) managing patients over 18 years old who are receiving physiological monitoring for Heart Failure surveillance and implanted with a compatible Cardiac Implantable Electronic Devices (CIED) (i.e., compatible pacemakers, ICDs, and CRTs). The SignalHF System provides additive information to use in conjunction with standard clinical evaluation. The SignalHF HF Score is intended to calculate the risk of HF for a patient in the next 30 days. This System is intended for adjunctive use with other physiological vital signs and patient symptoms and information and is not intended to independently direct therapy.
    See the instructions for use for more information.

Press Release

Implicity Earns FDA Clearance for New Heart Failure Prediction Algorithm

Cutting-edge tool analyzes data from cardiac remote monitoring devices to assess whether a patient is at high risk of experiencing worsening heart failure, enabling medical teams to intervene and avoid hospitalization.

May 17, 2024

Cambridge, Mass., May 17, 2024 – Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new groundbreaking algorithm, SignalHF*, used in its remote monitoring solution.

Implicity was the first private company authorized to access the Health Data Hub, one of the largest databases of patients with heart diseases in the world. Based on the Health Data Hub complete medico-administrative database and comprehensive datasets from Implicity’s AI-based remote monitoring platform, the Implicity team trained and validated a machine learning algorithm that assesses the risk of future heart failure events, enabling physicians to intervene before a patient requires hospitalization.

“Heart failure remains a significant healthcare challenge, contributing to approximately one million hospitalizations each year. Preventing even a portion of these would be a game-changer in cardiac care,” said Dr. Arnaud Rosier, Implicity’s CEO and cardiologist. “SignalHF is an innovative and effective tool that physicians can use to assess risk of hospitalization due to heart failure earlier, enabling interventions that can lead to better outcomes and reduce hospital admissions.”

SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of Cardiac Implantable Electronic Devices (CIED), including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices (CRT-P, CRT-D) from Biotronik, Boston Scientific and Medtronic. SignalHF is the first pacemaker compatible heart failure algorithm on the market. The algorithm can accurately identify trends indicating whether a patient’s condition is worsening. Care teams receive an automatic alert when the patient’s risk score crosses an established threshold, indicating an individual is at high risk of experiencing heart failure and being hospitalized in the near future.

“Comprehensive heart failure management includes treatment, prevention, and personalization. Implicity’s solution is part of this approach. Our alerts are generated in context with a patient’s medical profile to help personalize care management plans. Furthermore, 75% of the alerts preceding a patient hospitalization are sent at least 14 days in advance – offering a two-week window to adjust medications or take proactive measures,” said Issam Ibnouhsein, Head of Data at Implicity.

About Implicity
Implicity provides a remote monitoring and research platform used by Independent Diagnostic Testing Facilities and cardiac electrophysiology centers to deliver better, high-quality care for their patients with Cardiac Implantable Electronic Devices. Implicity’s platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers. Furthermore, Implicity carries out R&D on AI-based algorithms aiming at improving patient care and serving the future of preventive medicine. www.implicity.com

  1. *SignalHF is an FDA-cleared Class II medical device. See the instructions for use for more information.

Press Release

Implicity Joins the AWS ISV Accelerate Program

December 12, 2023

Cambridge, Mass., December 12, 2023 – Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. The program helps AWS partners drive new business by directly connecting participating ISCs with the AWS Sales organization.

“This is an important milestone that amplifies our reach and validates our mission to bring digital innovation to cardiology. By deepening our relationship with AWS, we can help even more clinicians improve cardiac care by delivering cutting-edge solutions that enable more efficient and effective remote monitoring,” said Jon Hunt, PhD., Implicity’s Chief Commercial Officer in North America.

Implicity’s AI-powered* platform allows healthcare professionals to better manage the growing streams of patient information produced by cardiac implantable electronic devices (CIEDs), such as pacemakers and implanted defibrillators. The solutions can also interpret data and automatically alert care teams when intervention is required.

The AWS ISV Accelerate Program provides Implicity with co-sell support that benefits to meet customer needs through collaboration with AWS field sellers globally. Co-selling provides better customer outcomes and assures mutual commitment from AWS and its partners.

« Before Implicity, our team would have spent hours weeding through alerts and reports. This would have delayed the treatment of patients with clinically significant events or critical episodes. Additionally, their customer support and service have been second to none. They are truly dedicated to helping clinicians streamline their care and optimize their workflow. This system is life-changing, » said Dan Morris, Device Clinic Lead at the Heart Center of Nevada.

AWS ISV Accelerate program members are held to the industry’s highest standards. To gain acceptance into the AWS ISV Accelerate Program, proof of customer excellence was required to validate the success users have experienced using the technology. Implicity also had to pass a rigorous technical and security review of its platform to ensure the quality and design of its solutions. The program gives Implicity-focused co-selling support and access to expanded sales enablement resources from AWS. It also provides technical enablement and business resources to enhance Implicity’s offerings and drive innovation.

About Implicity

Implicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure.

Implicity’s platform provides critical health information augmented by FDA-cleared AI* algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub**, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 94,000 patients in over 195 medical facilities across the US and Europe.

*FDA cleared Class II medical device, and CE marked Class I (under MDD) medical device; see the instructions for use for more information.
**Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Press Release

New Study Shows Algorithm Highly Effective at Identifying Patterns and Classifying AF Episodes.

October 24, 2023

Cambridge, Mass., October 24, 2023 – Implicity, a leader in remote patient monitoring (RPM) and cardiac data management solutions, today announced the results of a clinical study published in the Cardiovascular Digital Health Journal.

The findings show Implicity’s proprietary algorithm significantly reduced the number of alerts related to transmissions by cardiac implantable electronic devices (CIEDs) in patients being remotely monitored for atrial fibrillation (AF) by filtering standard device notifications and automatically classifying episodes that meet the threshold for clinical relevance.

“For a patient with AF who is already anticoagulated, a single AF episode isn’t as important as established patterns or occurrences associated with arrhythmia progression and patient outcomes. This study proved Implicity’s algorithm can reduce AF alert fatigue by effectively detecting trends, both positive and negative, and categorizing events that require intervention or adjustments in treatment,” said Jagmeet P. Singh MD MMSc DPhil

The retrospective study analyzed real-life data from more than 4,000 recipients of Abbott, Biotronik, Boston Scientific, or Medtronic CIED who were being continuously monitored for AF. Implicity compared the incidence of standard CIED-transmitted alerts from device manufacturers with the incidence of events detected after filtering by Implicity’s algorithm. Results showed the algorithm broke down 67,883 AF burden-related alerts into 9,728 (14.3%) clinically relevant AF events, according to the European Society of Cardiology classification. Notably, the median number of alerts per patient year decreased by 57.9%.

“Sending physicians only clinically relevant alerts, based on the detection of distinct presentations of AF, can reduce the time electrophysiologists spend reviewing notifications that don’t require action by several hours. This will increase the efficiency and quality of care of patients with AF, save time for the medical staff, and help promote the adoption of RPM – leading to more meaningful remote monitoring and ultimately better outcomes,” said Dr. Arnaud Rosier, electrophysiologist, CEO, and co-founder of Implicity.

Continuous remote monitoring is critical for properly managing patients with AF. It allows providers to track patients’ heart rhythms for early intervention and treatment, reducing complications such as stroke and heart failure. Yet a previous study published in European Heart Journal showed that atrial arrhythmia episodes account to up to 51% of the events clinicians are expected to review, suggesting that tackling these alerts could significantly reduce the alert burden.

Implicity’s algorithm works with any device that collects atrial burden trends data and can classify the following scenarios in line with ESC recommendations:

  • Paroxysmal AF
  • Persistent AF
  • Increasing paroxysmal AF
  • Back to sinus rhythm
  • Back to paroxysmal AF

About Implicity

Implicity is a digital MedTech software company dedicated to providing the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure.

Implicity’s platform provides critical health information augmented by FDA-cleared AI algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub**, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 94,000 patients in over 195 medical facilities across the US and Europe. To learn more, visit www.implicity.com

*CE marked class I medical device (MDD); see the instructions for use for more information.
** Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Press Release

Implicity Expands Senior Leadership Team with New U.S. Chief Commercial Officer

October 6, 2023

Cambridge, Mass., September 27, 2023 – Implicity®, a leader in remote patient monitoring and cardiac data management solutions, announced that Jon Hunt, PhD., has joined the company as its new Chief Commercial Officer (CCO) in North America.

In this role, Hunt will focus on business and sales strategies for the U.S. market to maximize growth, scale operations, and support technological innovations that help meet the growing demand for remote cardiac monitoring.

Hunt brings nearly four decades of experience in the cardiovascular medical device industry. Most recently, Hunt served as Executive Vice President and Chief Business Officer at HeartBeam (NASDAQ: BEAT), a cardiac technology company that developed the first 3D vector ECG platform for heart attack detection. As a vital member of the senior leadership team, he played a critical role in taking the company public.

Prior to HeartBeam, Hunt held multiple leadership positions at organizations such as the Medical Device Innovation Consortium (MDIC), Cryterion Medical, and Cameron Health. In addition, he served as President and CEO of Bardy Diagnostics, whose novel ECG monitoring system achieved US and European approval under his leadership. Hunt began his career with Cardiac Pacemakers (now Boston Scientific Corporation) as the Director of Clinical Programs.

“Having an executive of Jon’s caliber and experience is key to achieving our goal of becoming the leader in remote cardiac monitoring in the US market. Jon brings extensive experience in the CRM/EP market and a proven track record of scaling startup companies and building commercial teams. We look forward to his guidance and expertise as we continue to build on our successes and provide healthcare professionals nationwide with more effective solutions for managing heart disease,” said Dr. Arnaud Rosier, electrophysiologist, CEO, and founder of Implicity.

Hunt joins Implicity as the company hits several critical business inflection points. Implicity recently submitted for US FDA clearance for a machine learning algorithm that can predict acute heart failure, the world’s leading cause of hospitalization. In May, Implicity revealed ground-breaking research demonstrating its AI-powered solutions significantly improve outcomes for patients with cardiac implantable devices. This as the U.S. market for remote patient monitoring has experienced significant growth. According to recent reports, the industry is expected to reach a value of more than $25 billion by 2028.

“I could not be more excited to join the Implicity team at this important juncture,” said Hunt. “I’ve witnessed firsthand the healthcare ecosystem’s need for innovative solutions that can enable providers to monitor remote cardiac devices more effectively and analyze massive volumes of cardiac data more efficiently. The company and its AI-powered technology are poised to revolutionize cardiology care delivery and improve the lives of millions of people around the globe.”

About Implicity

Implicity is a digital MedTech software company that provides the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by Cardiac Electrophysiologist Arnaud Rosier, MD, Ph.D., the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants.

Implicity’s platform provides critical health information augmented by FDA-cleared AI algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub*, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 94,000 patients in over 195 medical facilities across the US and Europe. To learn more, visit www.implicity.com

* Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Press Release

Implicity CEO Selected to Participate in HRX 2023 Panel Discussion on AI

September 19, 2023

Cambridge, Mass., September 18, 2023 – Implicity, a leader in remote patient monitoring (RPM) and cardiac data management solutions, announced today that founder and CEO Arnaud Rosier, MD, PhD, has been selected to participate in a panel discussion at the upcoming HRX 2023 Digital Health Event in Seattle, WA. The discussion, AI-aided Remote Interventions – Will this Transform Healthcare Delivery & Outcomes, takes place September 22, 2023, at 2:30 pm (PDT).

As part of the discussion, Dr. Rosier intends to share insights on new international recommendations for remote monitoring of cardiovascular implantable devices (CIED) released at Heart Rhythm 2023 (HRS). The expert consensus validated the benefits of using third-party service and solution providers, such as Implicity, to ensure the highest standard of remote monitoring and improve patient outcomes.

“We recently published groundbreaking data that demonstrated our AI-powered cardiac remote monitoring technology saves lives and significantly improves health outcomes,” said Dr. Rosier, Electrophysiologist, CEO, and co-founder of Implicity. “I’m eager to join experts on this panel to explore key takeaways from the research and discuss how intelligent technologies can impact our healthcare system for the better now and into the future.”

Research unveiled at Heart Rhythm 2023 and led by Dr. Niraj Varma, a Professor of Medicine and consultant Electrophysiologist at the Cleveland Clinic, found patients monitored with Implicity’s alert-based platform experienced a remarkable 22% relative improvement in all-cause mortality compared to conventional RM methods.

In addition to taking part in the panel presentation, Implicity also plans to exhibit at the HRX 2023 event (Booth #704) to showcase its latest innovations and technology advancements. The remote monitoring platform incorporates AI and machine learning to enable fast and effective analysis and reporting of patient results collected by CIEDs.

About Implicity

Implicity is a digital MedTech software company that provides the best remote care to patients with cardiac implantable electronic devices and heart failure. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, Ph.D., the platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants.

Implicity’s platform provides critical health information augmented by FDA-cleared AI algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub*, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 94,000 patients in over 195 medical facilities across the US and Europe. To learn more, visit www.implicity.com

For more information or to schedule a meeting, visit Implicity

* Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Press Release

Implicity Study Presented in Late-Breaking Clinical Trial Session at Heart Rhythm 2023

May 22, 2023

Cambridge, Mass., May 22, 2023 – Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced the findings of a study presented during a late-breaking clinical trial session at the Heart Rhythm Society’s (HRS) annual meeting.

The research was conducted in collaboration with the French government’s Health Data Hub, using a nationwide database of health information from more than 68,000 patients. Implicity linked real-world data from patients with cardiac implantable electronic devices (CIEDs) to various remote monitoring (RM) methods, comparing differences in mortality rates, number of annual hospitalizations per patient, and cumulative duration of hospital stays in a year.

The results showed significant disparities in mortality rates based on the method of RM utilized. While all patients with RM experienced improved survival rates, Implicity’s universal, alert-based remote monitoring platform was associated with a greater performance compared to historical manufacturers’ solutions (Abbott, Boston Scientific, Medtronic).

Notably, patients monitored with Implicity’s platform experienced a remarkable 22% relative improvement in all-cause mortality when compared with conventional RM methods, even after adjusting for confounding factors such as age, gender, CIED type, year of implant and center size. Additionally, the study revealed a significant reduction in both the number of annual hospitalizations per patient (-4%) and cumulative duration of hospital stay within a year (-6%), further validating that alert-based systems like Implicity’s can lead to superior patient outcomes in cardiac care.

“We already know that remote patient monitoring saves lives. What data from this study shows is that clinical improvements vary a lot depending on how remote monitoring is performed. We saw significant improvement in mortality rates but also a decrease in hospitalizations when clinicians were supported by the Implicity platform rather than device manufacturer systems alone. This shows that the most committed teams with the best tools have the potential to achieve a better outcome for these patients. What’s remarkable is that these results occurred even before we launched our unique AI algorithms, so we can hope for even better results down the road.” said Implicity CEO and co-founder, Arnaud Rosier, MD, PhD.

For more information, visit: www.implicity.com

About Implicity

Implicity is a digital MedTech software company dedicated to providing the best remote care to patients with connected cardiac implantable electronic devices. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, PhD, our platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for patients with cardiac implants and heart failure.

Implicity’s platform provides critical health information augmented by FDA-cleared AI algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub*, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 80,000 patients in over 150 medical facilities across the US and Europe. To learn more, visit www.implicity.com

Original abstract results can be found here. Differences in results are due to methodological adjustments.

* Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Press Release

Implicity Introduces New Algorithm to Address Alert Fatigue in AF Care

April 18, 2023

New feature tackles atrial fibrillation burden, reducing the alerts for patients being treated with anticoagulant medication and highlighting clinically significant events.

Cambridge, Mass., April 12, 2023 – Implicity, a leader in remote patient monitoring and cardiac data management solutions, introduced a new algorithm designed to reduce alert fatigue in the remote monitoring of patients with atrial fibrillation (AF).

Implicity’s AF Alert Management feature addresses AF burden, reducing alerts for patients who are taking anticoagulants and have a low risk of complications while triggering notifications the relevant moment there is a significant change in a patient’s condition that requires intervention or adjustments to treatment.

“The AF Alert Management tool optimizes AFib burden management, allowing providers to focus on clinically significant events,” said Adélie Cerrato, Product Manager at Implicity. “AFib burden can vary greatly between individuals on anticoagulants or those who are not. Our new algorithm can differentiate between the two, quieting alerts associated with patients on medication and notifying providers with smart alerts when the burden exceeds the threshold for action. This, in turn, can lead to better patient outcomes as they receive appropriate care when needed.”

Continuous remote monitoring is critical for properly managing patients with AF. It allows providers to track patients’ heart rhythms for early intervention and treatment, reducing complications such as stroke and heart failure. The AF burden rate, or percentage of time spent in an irregular heartbeat state, is measured using various devices, such as Holter monitors, pacemakers, defibrillators, and implantable loop recorders (ILRs).

Implicity’s algorithm works with any device that collects atrial burden trends data and can classify the following scenarios in line with ESC recommendations:

  • Consider proposing therapies to the patient, such as ablation:
    • Paroxysmal AF
    • Increasing paroxysmal AF
    • Persistent AF
  • Evaluates the success of therapies:
    • Back to sinus rhythm
    • Back to paroxysmal AF

On average, cardiologists receive about 1,000 manufacturer’s alerts on atrial burden/month per every 1,000 patients. Reviewing these alerts manually can prove to be time-consuming and inefficient. Implicity’s AF Alert Management alleviates this pain point and has the potential to save hours of time each month, freeing up clinicians so they can focus on patient care.

About Implicity
Implicity is a MedTech software company dedicated to providing the best remote care to patients with connected cardiac implantable electronic devices. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, our platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for those with chronic heart failure conditions.

As the first and only cardiac implant remote monitoring company to receive FDA clearance for an AI-based algorithm, Implicity’s platform provides critical health information, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub*, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 80,000 patients in over 150 medical facilities across the US and Europe. To learn more, visit www.implicity.com

  1. *Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Press Release

Implicity Releases SMART on FHIR App

April 17, 2023

New feature tackles atrial fibrillation burden, reducing the alerts for patients being treated with anticoagulant medication and highlighting clinically significant events.

Cambridge, Mass., April 12, 2023 – Implicity, a leader in remote patient monitoring and cardiac data management solutions, introduced a new algorithm designed to reduce alert fatigue in the remote monitoring of patients with atrial fibrillation (AF).

Implicity’s AF Alert Management feature addresses AF burden, reducing alerts for patients who are taking anticoagulants and have a low risk of complications while triggering notifications the relevant moment there is a significant change in a patient’s condition that requires intervention or adjustments to treatment.

“The AF Alert Management tool optimizes AFib burden management, allowing providers to focus on clinically significant events,” said Adélie Cerrato, Product Manager at Implicity. “AFib burden can vary greatly between individuals on anticoagulants or those who are not. Our new algorithm can differentiate between the two, quieting alerts associated with patients on medication and notifying providers with smart alerts when the burden exceeds the threshold for action. This, in turn, can lead to better patient outcomes as they receive appropriate care when needed.”

Continuous remote monitoring is critical for properly managing patients with AF. It allows providers to track patients’ heart rhythms for early intervention and treatment, reducing complications such as stroke and heart failure. The AF burden rate, or percentage of time spent in an irregular heartbeat state, is measured using various devices, such as Holter monitors, pacemakers, defibrillators, and implantable loop recorders (ILRs).

Implicity’s algorithm works with any device that collects atrial burden trends data and can classify the following scenarios in line with ESC recommendations:

  • Consider proposing therapies to the patient, such as ablation:
    • Paroxysmal AF
    • Increasing paroxysmal AF
    • Persistent AF
  • Evaluates the success of therapies:
    • Back to sinus rhythm
    • Back to paroxysmal AF

On average, cardiologists receive about 1,000 manufacturer’s alerts on atrial burden/month per every 1,000 patients. Reviewing these alerts manually can prove to be time-consuming and inefficient. Implicity’s AF Alert Management alleviates this pain point and has the potential to save hours of time each month, freeing up clinicians so they can focus on patient care.

About Implicity
Implicity is a MedTech software company dedicated to providing the best remote care to patients with connected cardiac implantable electronic devices. Co-founded by cardiac electrophysiologist Arnaud Rosier, MD, our platform aggregates, normalizes, and standardizes data from any implantable cardiac device across all manufacturers, improving care for those with chronic heart failure conditions.

As the first and only cardiac implant remote monitoring company to receive FDA clearance for an AI-based algorithm, Implicity’s platform provides critical health information, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub*, one of the world’s largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 80,000 patients in over 150 medical facilities across the US and Europe. To learn more, visit www.implicity.com

  1. *Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Press Release

The Association of German Cardiologists BNK Lists the Telemonitoring System Offered by Implicity and HCSG

January 26, 2023

The Association of German Cardiologists BNK Service GmbH lists the telemonitoring system “hedy” from HCSG and IMPLICITY to cardiologists in private practice. As a unique cloud-based and vendor-independent platform for heart failure telemonitoring, hedy enables telemonitoring with external devices and implants from all major manufacturers via a common TMZ portal. This listing by BNK Service GmbH was made after intensive testing and based on positive references from cardiologists who are already using the hedy telemonitoring system today.

Since the beginning of 2022, telemonitoring patients with heart failure (cardiac insufficiency) has been part of the outpatient service offered by the statutory health insurance funds.

“We want telemonitoring for heart failure to reach all patients eligible for this innovative treatment method as quickly as possible. That is why we are pleased to have gained HCSG and IMPLICITY, two very capable partners for cardiology practices.”
Susanne Oldenburg of BNK Service GmbH.

To implement telemonitoring, a cardiology-led telemedicine center (TMZ) must use either external devices (scales, ECG and blood pressure monitors, and patient apps) or data from implants (special pacemakers and defibrillators). For this purpose, hedy offers a unique cloud-based platform for telemonitoring of heart failure, via which the data of implants from all major manufacturers and external devices can be displayed and evaluated automatically and independently of the manufacturer via a common TMZ portal. Hedy requires no IT installation or maintenance of IT systems in the physicianˈs office. Physicians can access HCSGˈs certified tele-nurse center, relieving their practices of routine tasks.

“Cardiologists need the support of competent service providers to operate a telemedicine center. The practices we interviewed reported their excellent experience, reliable service, and HCSGˈs profound expertise in monitoring with external devices. Implants from all major manufacturers can be connected via the IMPLICITY system. This provides cardiologists with a common portal for all forms of telemonitoring. We see this as a great advantage for patient care.”
Simon Glück, Managing Director of BNK Service GmbH.

BNK Service GmbH has intensively tested the technology and service offering around hedy. The consistently positive feedback from practices that operate a TMZ with hedy and have already gained sound experience in its use has convinced BNK Service GmbH. To date, around 350 physicians are using hedy telemonitoring. Users of hedy can be found in individual practices as well as in sizeable professional practice groups (joint practices) or medical care centers (MVZ).

“We want to ensure that all heart failure patients receive optimal care. Even those who find it difficult to get to the doctor because they live in rural areas or, in particular, the elderly patients. With hedy and the companies HCSG and IMPLICITY at our side, the start for this is quite easy, and we can
benefit from their years of experience. The direct accessibility and service canˈt be beaten.”
Dr. Placke specialist practice for cardiological primary and specialty care in Rostock, Germany.

“We had already preferred the hedy telemonitoring system based on recommendations from colleagues. The presentation of experienced users of the hedy solution for external devices and implants in the BNK webinars strengthened our decision. And we are starting with hedy in the new year.”
Dr. med. Gabelmann and Prof. Pottgießer, Cardiology Dreisamtal/Kirchzarten

Background:
Since the beginning of 2022, telemonitoring patients with heart failure (cardiac insufficiency) has been part of the outpatient service offered by the statutory health insurance funds. Telemonitoring can be prescribed to patients with heart failure (NYHA II – III and EF < 40) if they have been treated in the hospital in the last 12 months or if they wear a suitable implant.
To implement telemonitoring, a telemedicine center (TMZ) must use either external devices (scales, ECG and blood pressure monitors, and patient apps) or implants (special pacemakers and defibrillators). Hedy (https://hedy.de) refers to a system for telemedicine care of patients with heart failure. The solution is aimed at cardiologists who want to operate their own TMZ. Hedy is a registered trademark of Health Care Systems GmbH.

Cooperation partners:
HCSG specializes in telemonitoring with external devices, while IMPLICITY processes the data of implants from all major manufacturers for cardiologists. With the complete solution from HCSG and IMPLICITY, consisting of devices, software, service, and consulting, cardiologists can immediately set up their own TMZ (https://www.IMPLICITY.com/landing-page/partnership-IMPLICITY-x-hcsg/).

BNK Service GmbH (https://www.bnk-service.de/) is the subsidiary of the Bundesverband Niedergelassener Kardiologen (BNK) e.V., which represents more than 90 percent of the practicing cardiologists in Germany. BNK Service supports approximately 1,200 cardiologists in their daily practice. In addition, as a specialized service provider for the entire cardiology field, it networks all the players involved in care. As a central interface, BNK Service GmbH develops and manages comprehensive care concepts, conducts scientific surveys on care research, and thus provides a realistic picture of cardiological care in Germany.
Your contact: Simon Glück
Phone: +49 89 41 42 40 8-14, Email: simon.glueck@bnk-service.de

IMPLICITY (https://implicity.com) is a digital medical technology company that provides healthcare providers with a universal telemonitoring platform that aggregates and uniformly displays implantable cardiac implant data from all major manufacturers. In addition, IMPLICITY develops AI and knowledge-based algorithms to empower physicians and enable them to predict patient health status. IMPLICITY serves over 80,000 patients in more than 150 medical facilities in Europe and the US.
Your contact: Karsten Hagemann
Phone: +33 680 10 50 65, Email: karsten.hagemann@implicity.com

Health Care Systems GmbH (https://hcsg.de) is a leading provider of solutions for digital precision medicine. The HCSG team has more than 16 years of experience in telemedicine care for patients with heart failure. Today, HCSG serves patients throughout Germany and Switzerland with more than 60 employees at three locations. HCSG has developed the hedy Telemonitoring Program (https://hedy.de) specifically for use in telemedicine centers. The system is particularly easy to use because it is tailored to the needs of older people with severe chronic illnesses. Specialized nurses staff HCSG’s service center with special training in telephone care for people with heart failure. Health data is processed in a high-security data center in Germany.
Your contact: Christian Kloss
Phone: +49 89 444 889 102, Email: christian.kloss@hcsg.de

Read the press release in German
Read the brochure of our joint solution in German

Press Release

Implicity to Participate in Health Tech Challengers Super Finals at the HLTH 2022

November 8, 2022

Company named a Top 8 Super Finalist in the global health tech competition identifying the most disruptive companies shaping the future of digital health.

Cambridge, Mass., November 8, 2022 – Implicity®, a leader in remote patient monitoring and cardiac data management solutions, announced it has been selected to participate in the Health Tech Challengers (HTC) Super Finals taking place live at HLTH 2022.

The global competition identifies top companies fostering digital health innovation. Implicity won the Cardiovascular track and is one of only eight startups invited to pitch in-person at the live event in Las Vegas on November 15, 2pm at Venetian Ballroom D, Lvl 2, where the ultimate winner will be announced.

“We’re honored to be among such an impressive group of finalists. This recognition validates the positive impact our AI-powered platform is having on cardiologists and healthcare professionals who care for patients with CIEDs. These remote cardiac monitoring solutions are producing more and more data each year. The only way for clinicians to process it all is with artificial intelligence-based tools. We are proud to deliver a solution to the market that can improve day-to-day life for practitioners, and allow them to spend more time with their patients,” said Dr. Arnaud Rosier, electrophysiologist, CEO, and co-founder of Implicity.

Implicity’s AI algorithm that analyzes ECG data from implantable loop recorders (ILRs) received clearance from the Food and Drug Administration in late 2021. Earlier this year, the company announced $23M in Series A funding to accelerate expansion in the US and support the development of next-generation offerings that move toward the prevention of heart disease.

Health Tech Challenger finalists were selected by a distinguished panel of industry experts from leading corporations, Venture Capital, ecosystem builders, and media partners. For more on the competition, visit: ​​https://healthtechchallengers.com/#TOP8

About Implicity

Implicity® is a MedTech software company, cofounded by cardiac electrophysiologist Arnaud Rosier MD, that provides a universal cardiac remote monitoring and research platform to clinics and service companies – helping them provide the best remote care to cardiac patients. Implicity develops unique AI and knowledge-based algorithms with the potential to predict patient health status, which reduce the workload on healthcare professionals.

The Implicity platform aggregates, normalizes, and standardizes data from all implantable cardiac electronic devices across all major manufacturers and improves care for patients with chronic heart failure conditions. Implicity proudly protects more than 70,000 patients in 150+ medical facilities across the United States and Europe.

Media Contact:

Samantha Choinski

eMedia Junction

860-301-5058

samantha@emediajunction.com

Press Release

Implicity Continues Rapid Growth and Expansion with Hiring of Two New Senior Leaders

Industry veterans Vanessa Joyce named VP of Sales for North America and Megan Grosz appointed Head of Global Marketing and Communications

October 24, 2022

Cambridge, Mass., September 28th, 2022 – Implicity®, a leader in remote patient monitoring and cardiac data management solutions, announced its continued growth with the appointment of two new senior-level executives. Vanessa Joyce was named the Company’s new Vice President of Sales for North America and Megan Grosz was appointed Global Head of Marketing and Communications.

“We’re thrilled to welcome these two impressive leaders. Both Vanessa and Megan bring a wealth of industry knowledge to support our rapid global expansion, particularly in the U.S. where we see a dramatic rise in remote patient monitoring,” said Dr. Arnaud Rosier- Electrophysiologist, CEO, and Co-founder of Implicity.

Vanessa Joyce comes to Implicity with more than 30 years of experience in MedTech marketing and clinical aspects of the Cardiac, Heart Failure, and Electrophysiology industries. Prior to joining the Company, she served as the area director of sales for Rhythm Management Group. She also held sales leadership roles at Philips Healthcare, Medtronic, and St. Jude Medical.

“I’m excited to apply my expertise and experience to establish Implicity as the primary CIED remote monitoring software solution,” said Joyce. “We are building an extraordinary sales force to bring this unparalleled technology to providers and revolutionize care for CIED patients. This solution will help drive the adoption of RPM by helping cardiologists, electrophysiologists, and their teams manage the growing volume of data and false alerts that are becoming so difficult and time-consuming to review.”

To help communicate the unique benefits of Implicity’s automated cardiac remote monitoring platform, Megan Grosz is joining Implicity as Head of Global Marketing and Communications. She will leverage her sales and business development success to drive increased brand awareness and reach for Implicity with an emphasis on the recently FDA-approved AI algorithm that analyzes ECG episodes from Implantable Loop Recorders (ILRs). According to a study published in the European Heart Journal, applying the machine learning algorithm to ECG data collected by Medtronic’s ICMs decreased the false positive rate by nearly 80%.

Grosz previously served as the Director of Sales and Marketing at Omega Medical Imaging, a manufacturer of AI-enabled, image-guided interventional imaging systems for cardiology, electrophysiology, interventional radiology, and therapeutic endoscopy.

“There is a growing appetite for intelligent, cloud-based solutions that can improve the productivity and efficiency of care delivery. By handling data-intensive tasks and reducing false positive alerts, Implicity’s AI-powered platform can make a real difference in the lives of healthcare providers. All of this translates into better outcomes for patients,” said Grosz. “I look forward to sharing this unique solution with providers around the world.”

About IMPLICITY®

Implicity® is a digital MedTech company, – founded by cardiac electrophysiologist Arnaud Rosier MD – that provides a universal cardiac remote monitoring and research platform to clinics and service companies- helping them provide the best remote care to cardiac patients. Implicity develops unique AI and knowledge-based algorithms with the potential to predict patient health status, which reduce the workload on healthcare professionals.

The Implicity platform aggregates, normalizes, and standardizes data from all implantable cardiac electronic devices across all major manufacturers – and improves care for patients with chronic heart failure conditions. Implicity proudly protects more than 70,000 patients in more than 100 medical facilities across the United States and Europe.

Press Release

HCSG and IMPLICITY® Offer German Cardiologists a Complete Solution for Remote Monitoring

May 20, 2022

The two companies offer a complete solution for German telemedicine centers, including equipping patients with the devices and a TMZ portal for heart failure remote monitoring with external sensors and implants.

Munich and Paris, May 20th, 2022 — HCSG and IMPLICITY, two leading providers of remote monitoring solutions in the field of cardiology, announced today the conclusion of a cooperation agreement. The two companies’ offer is aimed at German cardiologists who want to operate their own telemedicine center (TMZ).

Remote monitoring of patients with cardiac insufficiency (heart failure) has recently become part of the outpatient services offered by the statutory health insurance funds. Remote monitoring can be prescribed topatients with heart failure if they have been hospitalized in the last 12 months or are wearing a suitable implant. To implement remote monitoring, a TMZ must use either external devices (scales, ECG, blood pressure monitors and patient app) or implants (dedicated pacemakers and defibrillators).

HCSG specializes in remote monitoring with external devices, while IMPLICITY processes implant data from all major manufacturers for cardiologists. With the complete solution from HCSG and IMPLICITY, consisting of devices, software, service and consulting, cardiologists can immediately set up their own TMZ. The system has already proven itself in practice:

« In our TMZ, we use both implants and external sensors for remote monitoring. All data is clearly displayed in a TMZ portal. This enables limit value analyses with the least possible effort, » says Dr. Ali Halboos from the GiG Telemedicine Center, Germany.

The Gesellschaft für integrierte Gesundheitsversorgung (GiG) operates 17 cardiological practices whose locations are mainly in NRW and southern Germany.

« Seeing the most important information from all manufacturers automatically and at a glance allows me to provide my patients with very efficient and optimal care in remote monitoring. The user-friendly implementation of the cloud-based platform is a concrete example of IMPLICITY’s many years of experience. One example: the automatic notification of patients for whom transmissions have failed makes our day-to-day work much easier », says Dr. Lutz Sinn from the practice for cardiovascular medicine in Bad Säckingen, Germany.

« I don’t want to worry about the issue of equipment, and I don’t want to have anything to do with it if there is a malfunction of the equipment or a problem with the data transmission. But I just want to know exactly when the patient is getting worse. That’s where we benefit from HCSG, which has already provided such services », says Prof. Dr. Martin Bergmann from the Cardiologicum Hamburg.

With over 60,000 treatment cases per year, the Cardiologicum Hamburg is one of the largest outpatient care centers for cardiovascular medicine in Germany.

About IMPLICITY®

IMPLICITY is a digital medical technology company that provides healthcare providers with a universal remote monitoring platform that aggregates data from implantable cardiac implants from all major manufacturers and presents it in a uniform manner.

IMPLICITY is also developing AI and knowledge-based algorithms to reduce the burden on physicians and enable them to predict the health status of patients. IMPLICITY serves more than 60,000 patients in 100 medical facilities in Europe and the US.

Contact:
Karsten Hagemann
Tel: +33 680 105065 | Email: karsten.hagemann@implicity.com

About HCSG

Health Care Systems GmbH is a leading provider of digital precision medicine solutions. The HCSG team has more than 15 years of experience in providing telemedical care to over 70,000 patients with heart failure. Today, HCSG serves patients throughout Germany and Switzerland with over 60 employees at three locations. HCSG has developed the hedy Telemonitoring Program specifically for use in telemedicine centers.

Contact:
Dr. med. Christian Kloss
Tel: 089 444 889 102 | Email: info@hcsg.de

Press Release

IMPLICITY Raises $23M to Broaden Use of Its Cardiac Remote Monitoring Platform

Series A funding round will accelerate international expansion and fuel AI-based medical algorithm development.

April 27, 2022

Cambridge, Mass., April 27th, 2022 – IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, today announced it has raised $23 million in Series A funding led by new investors: Crédit Mutuel Innovation and Bpifrance.

Additional investors for the round include BNP Paribas Development and previous seed investors: Serena, XAnge and Karista.

This new funding comes just months after IMPLICITY received FDA clearance for a novel AI algorithm that analyzes ECG episodes from Implantable Loop Recorders (ILRs).

“This financing round marks a new and exciting chapter for IMPLICITY. With clinical staff everywhere wrestling with an increasing volume of data coming from the growing number of connected devices, the need for a universal remote platform is now widely recognized as paramount. Coverage of remote care sparked by Covid-19 set the scene. In order to democratize remote cardiac care, our mission is to provide healthcare professionals with the best technology available to scale and monitor all cardiac patients,” said Dr. Arnaud Rosier, CEO and founder of IMPLICITY.

The new funding will help speed the international rollout of IMPLICITY’s AI-based technology and cardiac data management solutions — enabling healthcare professionals around the world with a more holistic approach to caring for cardiac patients. Proceeds will be used to:

  • Increase the company’s market presence in the US and support expansion into new markets
  • Develop additional medical device software to strengthen the technological leadership of the company

“We are very pleased to support the commercial expansion of IMPLICITY’s cutting-edge platform that enables cardiologists to provide more effective patient care by streamlining data across major remote cardiac monitoring devices,” said Delphine Cardi, Investment Director at Crédit Mutuel Innovation. “The company is already on a strong growth path in the U.S. and Europe, and we look forward to building on that momentum as they continue to develop next-generation offerings that move toward the prevention of heart disease.”
“We are extremely impressed by IMPLICITY’s current international market success. We believe the company has the potential to become a world-class leader in cardiac remote monitoring. This investment will help accelerate adoption across all regions in 2022 and beyond, particularly in the U.S. This is a very large market opportunity that cannot be overstated,” said Chahra Louafi, Director of the Autonomous Patient Fund at Bpifrance.

About IMPLICITY®
IMPLICITY® is a software company that provides a universal cardiac remote monitoring and research platform to clinics and service companies, helping them provide the best remote care to cardiac patients. As a digital Medtech, IMPLICITY® develops AI and knowledge based algorithms to reduce healthcare professionals’ workload and allows them to potentially predict patient health status.

The IMPLICITY® platform aggregates, normalizes and standardizes data from all implantable cardiac electronic device across all major manufacturers. In addition to having an FDA cleared solution and multiple CE markings, IMPLICITY® has been the first private company authorized to access the Health Data Hub*, one of the world’s largest patient databases     , supporting the development of its AI solutions to improve care for patients with chronic heart failure conditions. IMPLICITY® covers more than 60,000 patients in 100 medical facilities across the United States and Europe.

About Crédit Mutuel Innovation

Crédit Mutuel Innovation is the venture capital subsidiary of Crédit Mutuel Equity (€3.5 billion of capital under management), part of Crédit Mutuel Alliance Fédérale. It invests tickets between €1m and €20m in innovative companies in the digital, life sciences and deeptech sectors.

Crédit Mutuel Innovation enables entrepreneurs to develop their growth potential by connecting them to companies in the ecosystems it belongs. Because it takes more than five years to create a world leader, Crédit Mutuel Innovation invests (and often reinvests) its own capital on a long-term basis and builds long-term relationships with the entrepreneurs it supports.

About Bpifrance and FPA

Bpifrance‘s equity investments are made by Bpifrance Investissement. Bpifrance finances companies—at each stage of their development—​​with loans, guarantees and equity. Bpifrance supports them in their innovation projects and internationally. Bpifrance now also ensures their export activity through a wide range of products. Advice, university, networking and acceleration programs for startups, SMEs and ETIs are also part of the offer offered to entrepreneurs. Thanks to Bpifrance and its 50 regional locations, entrepreneurs benefit from a close, unique and efficient interlocutor to support them in facing their challenges. Bpifrance’s Autonomous Patient Fund, launched in early 2018, targets startups which develop innovations that allow:

  • Optimization of health costs—Better care by helping to strengthen the relationship between a health professional and his patient (telemedicine, remote monitoring, digital therapies),
  • An improvement in the quality and efficiency of care,
  • Improvements in the care pathway, in particular for chronic diseases (diabetes, cancers, mental health, etc.), by helping to prevent diseases and their complications, by facilitating the diagnosis of the disease and by monitoring its evolution over time real, in particular thanks to artificial intelligence, « deep/machine learning.”
  1. *Health Data Hub is a health data platform put in place by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.

Press Release

IMPLICITY® to Showcase New Artificial Intelligence-based Innovations in Remote Cardiac Monitoring at HRS 2022

April 19, 2022

A key highlight will include a Rhythm Theater presentation focused on the constraints and challenges of remote cardiac monitoring (RCM), as well as the impact of AI in managing ILR dataflows and transforming RCM into an opportunity for clinical research.

Cambridge, Mass., April 19th, 2022 – IMPLICITY®, a global leader in remote patient monitoring and cardiac data management solutions, is showcasing its portfolio of remote cardiac monitoring solutions at the upcoming Heart Rhythm 2022 (HRS 2022) in San Francisco, California, hosted by the Heart Rhythm Society, between April 29th and May 1st, 2022.

A key highlight will be a Rhythm Theater presentation titled, “Management of CIEDs with New Remote Monitoring Features: From Standard of Care to Artificial Intelligence,” on Friday, April 29, 2022, at 2:15 pm PST in the Innovation Expo, Booth 2155.

“Using CIEDs for remote monitoring (RM) is now considered the standard of care, but they add a significant burden for clinicians because they have a high false-positive rate. Our panel session will explore how novel technologies such as AI can significantly reduce this workload and help streamline clinic workflows,” said Dr. Arnaud Rosier, Ph.D., electrophysiologist, and CEO and co-founder of IMPLICITY®.

Key opinion leaders on the panel include:

  • Niraj Varma, MB, ChB, FACC, Professor of Medicine and Consultant Electrophysiologist at the Cleveland Clinic, who pioneered the use of remote monitoring technology for implantable devices. Varma will chair the session and discuss how artificial intelligence (AI) is transforming the management of implantable loop recorder (ILR) data.
  • Suneet Mittal, MD, FACC, FHRS, Director of the Electrophysiology Laboratory, and Associate Chief of Cardiology at The Valley Hospital in Ridgewood, New Jersey. He will share insights on remote monitoring as a standard of care, exploring various constraints and challenges.

As part of the session, Dr. Rosier will also explain how remote patient monitoring (RPM) can support opportunities for clinical research. IMPLICITY® recently launched a unique competition offering investigators a chance to gain free access to IMPLICITY®’s platform to support their studies with support from IMPLICITY®’s team of data scientists and engineers.

IMPLICITY® announced FDA clearance for its AI-powered ILR ECG Analyzer for Implantable Loop Recorders in December 2021. The company’s full suite of innovative solutions will be on display at the HRS 2022 event at booth #1641.

About IMPLICITY®
IMPLICITY® is a digital MedTech that provides a universal remote cardiac monitoring and research platform to medical centers and service companies, helping them provide the best remote care to cardiac patients. IMPLICITY® develops AI and knowledge based algorithms to reduce healthcare professionals workload and allow to potentially predict patient health status.

The IMPLICITY® platform aggregates, normalizes and standardizes data from all implantable cardiac electronic device across all major manufacturers. In addition to having an FDA cleared solution and multiple CE markings, IMPLICITY® has been the first private company authorized to access the Health Data Hub*, one of the world largest patient database, supporting the development of its AI solutions to improve care for patients with chronic heart failure condition. IMPLICITY® covers more than 60,000 patients in 100 medical facilities across the United States and Europe. For more information, visit: https://implicity.com

  1. *Health Data Hub is a health data platform put in place by the French government to combine existing health patient databases and facilitate their usage for research and development purposes

Press Release

Implicity Hosts US Research Competition for Free Access to Advanced AI-powered Cardiac Remote Monitoring Platform

Clinical and academic researchers can apply for one of three spots for free access to cardiac remote monitoring and ILR ECG Analyzer to support CRM research

March 11, 2022

Cambridge, Mass., March 10th, 2022 – Implicity, a leader in AI-powered remote patient monitoring and cardiac data management solutions, today announced an invitation for US-based researchers who are looking to conduct a study in the field of Cardiac Rhythm Management to apply for free access to Implicity’s cardiac remote monitoring software, including the ILR ECG Analyzer* & Advanced Research Tool. This is an opportunity for investigators to use highly-intelligent cardiac remote care & research solutions to support their studies for a minimum of one year, with support from Implicity’s team of data scientists and engineers.

“Research is at the heart of what we do at Implicity. Our solution is already the official remote monitoring platform of one of the largest research consortiums in Europe, our goal now is to support academic medical centers, physicians, and researchers in the US as we look to improve the treatment and diagnosis of cardiovascular diseases. We are excited to host this unique research competition, provide study support through our device-agnostic platform, and learn of the findings from these studies,” said Dr. Arnaud Rosier, CEO, and founder of Implicity.

Cardiac remote monitoring has already been shown to reduce the number of unnecessary emergency department visits and improve the time to diagnose clinical events. As the adoption of RM continues to grow, more studies will be needed to measure the ongoing impact of emerging technologies and new applications. From managing patient data content forms to organizing cross-device data, the Implicity platform is an effective tool that researchers can use to drive more efficient operations while also enabling scale.

Implicity’s research competition is open to physicians, medical interns, physician groups, academic facilities, PhDs, PhD students or other allied health professionals based in the United States, leading studies that involve remote monitoring data from cardiac implantable electronic devices (CIEDs), ILR ECG analysis, or other areas related to cardiac remote monitoring.

The deadline to apply is Tuesday May 10th, 2022. A panel of industry judges will make decisions shortly thereafter – the panel includes Prof. Jagmeet Singh (Boston, MA), Prof. Niraj Varma (Cleveland, OH/London, ENG) and Dr. Suneet Mittal (Paramus, NJ/New York City, NY).

Winners receive free access to Implicity’s AI-powered Cardiac Remote Monitoring platform and features, including the ILR ECG Analyzer and the Advanced Research Tool module, for a minimum of 12 months.

For application instructions and proposal requirements, visit: https://implicity.com/landing-page/research_contest/ or reach out directly to Implicity at researchcontest@implicity.com

About Implicity
Implicity provides an AI-powered remote monitoring and research platform used by Independent Diagnostic Testing Facilities and cardiac electrophysiology centers worldwide to deliver advanced high-quality care for their patients with connected CIEDs. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers. Furthermore, Implicity carries out R&D on AI-based algorithms aiming at improving patient care and serving the future of preventive medicine. Implicity is the first private company authorized to access the Health Data Hub**, one of largest databases of patients with heart diseases in the world, supporting the development of its ground-breaking AI solutions. Implicity covers 70,000 patients in over 100 medical facilities across Europe and the United States.

* FDA cleared Class II medical device and CE marked Class I (under MDD) medical device, see the instructions for use for more information.

** Health Data Hub is a health data platform put in place by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.